Beam Therapeutics (BEAM) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
63.5M
Operating Income
-415.6M
-654.25%
Net Income
-376.7M
-593.13%
EPS (Diluted)
-$4.58
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
370.3M
Shareholders Equity
733.5M
Debt to Equity
0.50
Cash Flow Metrics
Operating Cash Flow
-273.3M
Free Cash Flow
-356.2M
Revenue & Profitability Trend
Beam Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 63.5M | 377.7M | 60.9M | 51.8M | 24.0K |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 479.1M | 554.2M | 399.4M | 444.3M | 132.8M |
| Operating Income | -415.6M | -176.5M | -338.5M | -392.5M | -132.8M |
| Pre-tax Income | -376.7M | -131.2M | -260.2M | -370.6M | -194.6M |
| Income Tax | 39.0K | 1.4M | 3.4M | 0 | 0 |
| Net Income | -376.7M | -132.5M | -289.1M | -370.6M | -194.6M |
| EPS (Diluted) | -$4.58 | -$1.72 | -$4.13 | -$5.77 | -$4.19 |
Income Statement Trend
Beam Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 878.1M | 1.2B | 1.1B | 1.3B | 308.3M |
| Non-Current Assets | 225.7M | 248.7M | 248.8M | 201.4M | 143.4M |
| Total Assets | 1.1B | 1.5B | 1.3B | 1.5B | 451.7M |
| Liabilities | |||||
| Current Liabilities | 182.1M | 205.6M | 223.6M | 213.4M | 102.3M |
| Non-Current Liabilities | 188.2M | 272.8M | 384.6M | 434.3M | 103.8M |
| Total Liabilities | 370.3M | 478.4M | 608.2M | 647.7M | 206.1M |
| Equity | |||||
| Total Shareholders Equity | 733.5M | 981.3M | 733.5M | 826.7M | 245.6M |
Balance Sheet Composition
Beam Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -376.7M | -132.5M | -289.1M | -370.6M | -194.6M |
| Operating Cash Flow | -273.3M | -191.7M | 75.2M | -94.2M | -159.2M |
| Investing Activities | |||||
| Capital Expenditures | -8.9M | -33.7M | -49.0M | -46.8M | -16.4M |
| Investing Cash Flow | 185.0M | 71.8M | -461.3M | -294.1M | -100.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -485.0K | 267.3M | 105.8M | 746.5M | 319.2M |
| Free Cash Flow | -356.2M | -182.9M | -26.4M | -113.1M | -112.1M |
Cash Flow Trend
Beam Therapeutics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.65
Forward P/E
-3.50
Price to Book
1.45
Price to Sales
26.43
PEG Ratio
-3.50
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-1,596.87%
Return on Equity
-38.04%
Return on Assets
-19.05%
Financial Health
Current Ratio
8.81
Debt to Equity
14.08
Beta
2.08
Per Share Data
EPS (TTM)
-$4.61
Book Value per Share
$11.52
Revenue per Share
$0.76
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| beam | 1.7B | -3.65 | 1.45 | -38.04% | 0.00% | 14.08 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.